InflaRx N.V. (IFRX) vs Lineage Cell Therapeutics, Inc. (LCTX)
- InflaRx N.V. IFRX 1.32 −8.33%
- Lineage Cell Therapeutics, Inc. LCTX 0.98 −1.01%
InflaRx N.V. and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. is the larger, with a market value of $250.5M against $212.2M — 1.2× the size. Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −83.4%. InflaRx N.V. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 16 metrics below, InflaRx N.V. leads on 11 and Lineage Cell Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | IFRX | LCTX | Biotechnology median |
|---|---|---|---|
| Gross margin | (26,762.42%) | 99.46% | 65.16% |
| Operating margin | 0.00% | (205.23%) | 0.00% |
| Net margin | 0.00% | (246.58%) | 0.00% |
| Free cash flow margin | 0.00% | (186.43%) | 0.00% |
| Return on equity | (38.71%) | (60.35%) | (56.36%) |
| Return on assets | (32.75%) | (32.75%) | (48.04%) |
| Return on invested capital | 0.00% | (186.79%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack